Patents by Inventor GLEN J. WEISS

GLEN J. WEISS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MoT cells as a therapeutic screening tool for regulatory t-cell activity
    Patent number: 11391726
    Abstract: The present invention includes a method for screening one or more agents that modulate Regulatory T cell (Treg) activity, the method comprising the steps of: incubating a population CD4+ cells isolated from human blood peripheral mononuclear cells the CD4+ cells in contact with MoT cells in the presence of the one or more agents suspected of modulating Treg activity; detecting activation of the CD4+ cells without or with the agent; and comparing the activation of the CD4+ cells without or with the agent, wherein a change in activation following incubation with the agent relative to the activation of the PBMCs following incubation without the agent indicates that the agent is a modulator of Treg activity.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: July 19, 2022
    Assignees: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY, MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
    Inventors: Douglas Lake, Thai H. Ho, Glen J. Weiss
  • MOT CELLS AS A THERAPEUTIC SCREENING TOOL FOR REGULATORY T-CELL ACTIVITY
    Publication number: 20210270807
    Abstract: The present invention includes a method for screening one or more agents that modulate Regulatory T cell (Treg) activity, the method comprising the steps of: incubating a population CD4+ cells isolated from human blood peripheral mononuclear cells the CD4+ cells in contact with MoT cells in the presence of the one or more agents suspected of modulating Treg activity; detecting activation of the CD4+ cells without or with the agent; and comparing the activation of the CD4+ cells without or with the agent, wherein a change in activation following incubation with the agent relative to the activation of the PBMCs following incubation without the agent indicates that the agent is a modulator of Treg activity.
    Type: Application
    Filed: September 25, 2019
    Publication date: September 2, 2021
    Inventors: Douglas LAKE, Thai H. HO, Glen J. WEISS
  • METHODS OF DETERMINING CHEMOTHERAPY RESPONSE IN CANCER
    Publication number: 20120245044
    Abstract: This disclosure provides a biomarker profile, which is linked to cancer cell chemo-resistance. The disclosure further provides methods of diagnosis and theranosis, and screening of new therapeutic agents using these biomarkers in the profile, and kits for employing these methods and compositions.
    Type: Application
    Filed: March 26, 2012
    Publication date: September 27, 2012
    Applicant: TRANSLATIONAL GENOMICS RESEARCH INSTITUTE
    Inventor: Glen J. Weiss
  • METHODS AND KITS TO PREDICT PROGNOSTIC AND THERAPEUTIC OUTCOME IN SMALL CELL LUNG CANCER
    Publication number: 20110171323
    Abstract: Disclosed herein are methods used in the identification of cancer patients likely or unlikely to respond to systemic chemotherapy, methods of treating cancer patients based upon the identification, and kits that facilitate the identification. The methods and kits involve detecting the expression of specific microRNA.
    Type: Application
    Filed: January 8, 2011
    Publication date: July 14, 2011
    Applicants: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE, SCOTTSDALE HEALTHCARE
    Inventor: GLEN J. WEISS